Salivary uric acid remote serial self‐testing for prediction of adverse pregnancy outcomes of uteroplacental dysfunction
Acta Obstetricia et Gynecologica Scandinavica · 2026-09 · 105 (9) · 1761-1766
DOI: 10.1111/aogs.70257 ↗At a glance
Beobachtungsstudie in Acta Obstetricia et Gynecologica Scandinavica, published online on 2026-05-14. Written by Basia Chmielewska and 4 co-authors. Institution: Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, London, UK. Major MEDLINE topics: Uric Acid, Fetal Growth Retardation, Saliva, Hypertension, Pregnancy-Induced. 23 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Introduction
Hypertensive disorders of pregnancy (HDP) and fetal growth restriction (FGR) are major manifestations of uteroplacental dysfunction and remain leading causes of maternal and perinatal morbidity. Current strategies for risk assessment rely on hospital‐based screening or diagnostic triage and do not provide continuous, personalized monitoring throughout pregnancy. Uric acid is closely linked to placental dysfunction, and salivary uric acid (sUA) reflects circulating concentrations, enabling noninvasive remote measurement. This study evaluated whether serial, smartphone‐enabled self‐testing of sUA could predict adverse pregnancy outcomes related to uteroplacental dysfunction. Material and Methods In this prospective observational cohort study, pregnant women were recruited at 20–22 weeks' gestation at a tertiary hospital. Participants performed weekly salivary self‐testing using colorimetric uric acid strips until delivery, with results captured via a smartphone application. Images were analyzed using RGB color metrics. Primary outcomes were HDP and/or FGR, defined using ISSHP and FIGO criteria, respectively. Logistic regression models incorporated 4 weeks of lagged RGB‐derived sUA metrics together with maternal characteristics. Model performance was assessed using area under the receiver operating characteristic curve (AUC) and calibration metrics, stratified by gestational age at outcome.
Results
Of 495 recruited participants, 318 women with complete longitudinal data were included in the final analysis; 36 (11.3%) developed HDP and/or FGR. A multivariable model combining maternal risk factors with 4 weeks of serial sUA measurements demonstrated good predictive performance. Discrimination was highest for preterm outcomes, with an AUC of 0.814 for prediction within 1 week at
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, London, UK.
- Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, City St George's University of London, London, UK.
- Kingston University, London, UK.
- London Women's Clinic, London, UK.
- Zealand University Hospital, Roskilde, Denmark.
ORCID profiles: Basia Chmielewska
Cite
APA
Chmielewska, B., Wang, C., Macklon, N., Bhide, A., & Thilaganathan, B. (2026). Salivary uric acid remote serial self‐testing for prediction of adverse pregnancy outcomes of uteroplacental dysfunction. Acta Obstetricia et Gynecologica Scandinavica, 105(9), 1761-1766. https://doi.org/10.1111/aogs.70257
Vancouver
Chmielewska B, Wang C, Macklon N, Bhide A, Thilaganathan B. Salivary uric acid remote serial self‐testing for prediction of adverse pregnancy outcomes of uteroplacental dysfunction. Acta Obstetricia et Gynecologica Scandinavica. 2026;105(9):1761-1766. doi:10.1111/aogs.70257
BibTeX
@article{Chmielewska2026,
author = {Chmielewska, Basia and Wang, Chao and Macklon, Nick and Bhide, Amar and Thilaganathan, Basky},
title = {Salivary uric acid remote serial self‐testing for prediction of adverse pregnancy outcomes of uteroplacental dysfunction},
journal = {Acta Obstetricia et Gynecologica Scandinavica},
year = {2026},
volume = {105},
number = {9},
pages = {1761--1766},
doi = {10.1111/aogs.70257}
}
EUVIMED